AstraZeneca PLC filed a Form 6-K with the SEC on 2 November 2026, disclosing its total voting rights as at 31 October 2026 in accordance with UK Financial Conduct Authority Disclosure and Transparency Rule 5.6.1.

Key Highlights

  • Total voting shares: AstraZeneca's issued share capital with voting rights stood at 1,551,065,237 ordinary shares of US$0.25 as at 31 October 2026.
  • No treasury shares: According to the filing, no shares are held in Treasury.
  • Total voting rights: The filing confirms the total number of voting rights is 1,551,065,237.
  • Regulatory basis: The disclosure was made under UK FCA Disclosure and Transparency Rule 5.6.1.
  • Exchange listing: The company is listed on LSE, STO, and NYSE:AZN, according to the filing.
  • Signatory: The report was signed by Matthew Bowden, Company Secretary of AstraZeneca PLC, dated 2 November 2026.

AstraZeneca's October 2026 Share Capital and Denominator Disclosure

AstraZeneca PLC, a global biopharmaceutical company focused on prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal and Metabolism, and Respiratory and Immunology, filed this notification to satisfy its obligations under the UK FCA's Disclosure and Transparency Rules. The company is headquartered at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, and reports that its medicines are sold in more than 125 countries.

According to the filing, as at 31 October 2026, AstraZeneca's issued share capital carrying voting rights comprised 1,551,065,237 ordinary shares, each with a nominal value of US$0.25. The filing states that no shares are held in Treasury, meaning the total number of voting rights equals the full issued share count of 1,551,065,237. The company disclosed that this figure is intended to serve as the denominator that shareholders may use to calculate whether they are required to notify their interest, or a change to their interest, in AstraZeneca PLC under the relevant FCA Disclosure and Transparency Rules.

The Form 6-K was submitted as a report of a foreign private issuer pursuant to Rule 13a-16 of the Securities Exchange Act of 1934. The registrant indicated it files annual reports under Form 20-F and confirmed it is not furnishing information pursuant to Rule 12g3-2(b). The filing carries Commission File Number 001-11960.

What Was Disclosed

AstraZeneca PLC disclosed its total issued share capital with voting rights as at 31 October 2026, confirming 1,551,065,237 ordinary shares of US$0.25 each, with no treasury shares held, in a Form 6-K filed on 2 November 2026.